BioSpace News Archive

Two regional orthopedic groups team up to strengthen patient-centered approach to orthopedic care.

Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias and part of Johnson & Johnson Medical Devices Companies*, announced today the launch of the #UnitedbyVision campaign.

Sareum Holdings plc (AIM: SAR), the specialist small molecule drug development business, notes that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, has announced that its Chief Scientific Officer, Dr. Christian Hassig, will present “Addressing Intrinsic & Acquired PARP Inhibitor (PARPi) Resistance Through Chk1 Inhibition” at the DNA Damage Response (DDR) Therapeutics Summit in Boston, MA.

The treatment of patients in clinical practice relies on the results of randomized clinical trials. The statistical methods currently used to test the treatment effects in such trials take into account a single criterion called “primary endpoint”.

Attune Pharmaceuticals, Inc., a biotechnology company focused on the discovery and development of novel, orally-administered, small molecule therapeutics for the treatment of rare diseases, today announced the completion of a $23 million Series B financing.

Thrombectomy is a surgical procedure to remove the blood clots formed in the blood vessel. Cerebral infraction is an ischemic stroke that results in lack of blood supply to the brain. Neurovascular thrombectomy devices also known as cerebral thrombectomy devices are used to retrieve or destroy the blood clots in the cerebral region.

Cardinal Health (NYSE: CAH) today announced that Brian Rice will join the company as executive vice president, chief information officer and customer support services. Rice’s most recent role was senior vice president, chief information officer and global business services for Kellogg Company.

Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced receipt of notification from the U.S. Food and Drug Administration (FDA) that the Company’s ongoing Phase 3, randomized, double-blinded, placebo-controlled, pivotal study of axalimogene filolisbac (AXAL) in high-risk, locally advanced cervical cancer (AIM2CERV) has been placed on partial clinical hold.

ConMed Corporation (NASDAQ: CNMD) today announced that it intends to offer, subject to market conditions and other factors, $275 million aggregate principal amount of its convertible senior notes due 2024 in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

First Quarter 2019 Summary